Intuitive Surgical falls 1.3% as FDA submission for next‑generation endoscope is reported

What happened

Intuitive Surgical (ISRG) fell 1.3% to close at $422.06 on October 13, 2026, after Zacks Investment Research reported it had submitted a next‑generation robotic endoscope to the U.S. Food and Drug Administration. The session was an ordinary one for the stock, so the regulatory submission is presented as the main development around the company rather than a proven cause of the price move. The S&P 500 was unchanged on the day, and the healthcare sector median fell 2.5%, with the stock performing 1.2 percentage points better than the sector median.

How big was the move

The stock opened 0.6% above the previous close and traded with volume 0.8 times its 20-day average, indicating lighter-than-normal activity. Over the last five sessions the stock rose 4.3%, while the S&P 500 over five sessions fell 0.2%, so recent short-term momentum favored Intuitive Surgical. The move on October 13 was 0.6 times a typical daily move for this stock, consistent with the classification of an ordinary session. The stock has a beta of 1.21, indicating the stock tends to move more than the market.

The technical picture

The stock traded 4.1% above its 20-day moving average and 8.6% above its 50-day moving average, but 4.5% below its 200-day moving average. The 50-day average is below the 200-day average, a sign of a weak longer-term trend. The Relative Strength Index (14 days) was 64, inside a neutral range between 30 and 70. Shares sat 30.1% below the 52-week high, highlighting how the recent gains still leave the stock well under its peak over the past year. Over one month the stock rose 11.7% and over three months it rose 8.5%; over one year it fell 1.8% and is 20.9 percentage points behind the S&P 500. Volatility was 34% annualized over 60 days, higher than 61% of its own readings over five years.

The technicals point to a meaningful short-term recovery from recent lows but also to caution for trend-following investors, given the 50-day average sits below the 200-day average. The neutral RSI suggests neither overbought nor oversold conditions.

Fundamentals and valuation

For the four quarters through June 30, 2026, Intuitive Surgical reported revenue of $11.03 billion, which grew 20.7% from a year earlier. Diluted earnings per share for that period were $8.79, which rose 22.6% from a year earlier. Gross margin was 66.7% (a year earlier: 66.6%) and operating margin was 31.3% (a year earlier: 28.8%). Free-cash-flow margin was 29.2% and return on invested capital was 15.1%. The company held net cash of $2.76 billion, and share count over one year decreased by 1.5%.

On valuation, the stock traded at 48.0 times trailing earnings and 39.1 times expected earnings, with a free-cash-flow yield of 2.2%. Its price to trailing earnings was lower than 95% of its own readings over the past five years (five-year median: 69.7 times earnings), underscoring that, despite a high absolute multiple, the current valuation is relatively modest versus recent history. PromtFinance scores ranked Intuitive Surgical positively on Value (75), Growth (73), Revisions (70) and strongly on Quality (83) and Stability (83); Momentum scored 46 (Neutral). Together, those measures reflect strong profitability and stability, solid growth, but muted momentum in the stock price.

Earnings and analyst expectations

Intuitive Surgical’s next report was scheduled for October 20, 2026. The last report, on July 16, 2026, showed earnings per share of $2.80 against $2.48 expected, 12.9% above estimates. The company had a streak of 14 consecutive quarters beating estimates, with an average surprise over the last four reports of 14.1% above estimates. The typical two-day reaction after recent reports was that the stock rose 0.3%.

Analysts’ consensus price target was $480.78, which was 13.9% above the closing price on October 13, 2026. Fifty-seven analysts covered the stock; seventy percent of analysts rated the stock as Buy or better, and the consensus rating was Buy. Those figures reflect continued analyst confidence rooted in the company’s revenue and earnings growth as well as its free-cash-flow generation.

What to watch

• October 20, 2026: next earnings report date.
• Zacks Investment Research report: submission of a next‑generation robotic endoscope to the U.S. Food and Drug Administration.
• Consensus price target $480.78, 13.9% above the closing price.
• Four quarters through June 30, 2026: revenue $11.03 billion, grew 20.7%.
• Price to trailing earnings 48.0 times trailing earnings.